News | March 16, 2026
QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Subscribe To Our Newsletter & Stay Updated
